Vericel Co. (NASDAQ:VCEL) Shares Acquired by Natixis Advisors L.P.

Natixis Advisors L.P. grew its stake in shares of Vericel Co. (NASDAQ:VCELFree Report) by 61.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 40,163 shares of the biotechnology company’s stock after purchasing an additional 15,304 shares during the period. Natixis Advisors L.P.’s holdings in Vericel were worth $1,430,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Conestoga Capital Advisors LLC boosted its position in shares of Vericel by 4.9% during the 4th quarter. Conestoga Capital Advisors LLC now owns 2,339,960 shares of the biotechnology company’s stock worth $83,326,000 after purchasing an additional 109,215 shares in the last quarter. New York State Common Retirement Fund boosted its position in shares of Vericel by 2.8% during the 3rd quarter. New York State Common Retirement Fund now owns 1,091,682 shares of the biotechnology company’s stock worth $36,593,000 after purchasing an additional 30,123 shares in the last quarter. William Blair Investment Management LLC boosted its position in shares of Vericel by 59.5% during the 3rd quarter. William Blair Investment Management LLC now owns 855,207 shares of the biotechnology company’s stock worth $28,667,000 after purchasing an additional 318,916 shares in the last quarter. FMR LLC boosted its position in shares of Vericel by 39.5% during the 3rd quarter. FMR LLC now owns 571,298 shares of the biotechnology company’s stock worth $19,150,000 after purchasing an additional 161,652 shares in the last quarter. Finally, Federated Hermes Inc. boosted its position in shares of Vericel by 21.2% during the 4th quarter. Federated Hermes Inc. now owns 560,419 shares of the biotechnology company’s stock worth $19,957,000 after purchasing an additional 97,952 shares in the last quarter.

Insider Activity at Vericel

In related news, CEO Dominick Colangelo sold 17,500 shares of the business’s stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $44.59, for a total value of $780,325.00. Following the completion of the transaction, the chief executive officer now owns 195,307 shares of the company’s stock, valued at approximately $8,708,739.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $44.59, for a total transaction of $780,325.00. Following the completion of the transaction, the chief executive officer now owns 195,307 shares of the company’s stock, valued at approximately $8,708,739.13. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Michael Halpin sold 7,874 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $44.71, for a total transaction of $352,046.54. Following the transaction, the chief operating officer now directly owns 949 shares of the company’s stock, valued at approximately $42,429.79. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,267 shares of company stock valued at $2,450,996. 7.20% of the stock is owned by insiders.

Vericel Trading Up 1.8 %

Shares of VCEL stock opened at $49.41 on Thursday. The firm has a 50-day moving average price of $47.53 and a 200 day moving average price of $42.07. Vericel Co. has a twelve month low of $30.18 and a twelve month high of $53.05. The company has a market capitalization of $2.40 billion, a price-to-earnings ratio of -4,936.06 and a beta of 1.74.

Vericel (NASDAQ:VCELGet Free Report) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. Vericel had a net margin of 0.22% and a return on equity of 0.21%. The firm had revenue of $51.28 million during the quarter, compared to the consensus estimate of $49.07 million. During the same quarter in the previous year, the company posted ($0.16) EPS. The firm’s revenue for the quarter was up 25.0% on a year-over-year basis. As a group, research analysts predict that Vericel Co. will post 0.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VCEL has been the subject of several research reports. HC Wainwright lifted their price target on Vericel from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. StockNews.com downgraded Vericel from a “hold” rating to a “sell” rating in a research note on Friday, May 10th. Truist Financial reaffirmed a “buy” rating and set a $54.00 price target on shares of Vericel in a research note on Tuesday, March 26th. Finally, TheStreet raised Vericel from a “d+” rating to a “c-” rating in a research note on Monday, January 29th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $46.80.

Get Our Latest Stock Report on Vericel

About Vericel

(Free Report)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Featured Stories

Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Co. (NASDAQ:VCELFree Report).

Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.